Medical Marijuana Reimbursement Improved Pain and Reduced Opioid Use in Workers’ Compensation Case, Study Finds
- The study evaluated the feasibility of reimbursing medical marijuana through workers’ compensation for a carefully selected chronic pain patient within a coordinated care model in Colorado.
- The patient experienced notable improvements, including reduced pain, better physical function and quality of life, and decreased opioid use by 17%, without any adverse safety events.
- The program emphasized the need for structured clinical oversight, communication with physicians, and consideration of workplace safety, and is suitable only for a limited group of carefully screened patients.
- Findings are based on a single patient, so results cannot be generalized broadly, but suggest medical cannabis reimbursement could be viable for select workers' compensation cases under close monitoring.
Reimbursing medical marijuana through workers’ compensation may be feasible for carefully selected patients with chronic pain, according to a study published in the Journal of Occupational & Environmental Medicine.
The study, titled “Medical Cannabis Reimbursement in Workers’ Compensation: Insights From a Program Evaluation in Colorado,” evaluated a patient enrolled in the Colorado Division of Workers’ Compensation’s Alternative Pain Management Program.
Researchers affiliated with the Colorado Department of Labor and Employment, Leaf411 and Amarimed of Colorado examined whether medical marijuana could be reimbursed safely within a coordinated workers’ compensation care model.
The program combined reimbursement for medical marijuana with care coordination and extensive clinical oversight. Researchers collected health and treatment outcomes at the beginning of the program and throughout the following 12 months.
By the end of the program, the patient reported meaningful reductions in pain, improved physical functioning and mobility, a better quality of life and increased psychosocial stability. No adverse safety events were reported.
The patient also voluntarily reduced monthly opioid consumption by 17% as symptoms became more manageable. The program did not require the participant to taper or discontinue opioids.
Since the study data was finalized, the Colorado Division of Workers’ Compensation says the participant has discontinued both opioids and THC and now relies exclusively on less psychoactive cannabinoids.
“The program demonstrated the feasibility of reimbursing medical cannabis under a coordinated care model,” researchers said.
The evaluation focused primarily on whether reimbursement could be implemented within the workers’ compensation system rather than determining whether medical marijuana is broadly effective for chronic pain.
Because the program evaluation involved a single patient, the findings cannot establish that similar outcomes would occur among the wider population of people receiving workers’ compensation benefits.
Researchers also emphasized that the approach would be appropriate only for a limited group of carefully screened patients and would require structured clinical monitoring, communication with treating physicians and attention to workplace impairment and safety risks.
“This program evaluation suggests that medical cannabis reimbursement may be a viable option for very select workers’ compensation patients,” researchers concluded.